

Timor-Leste

Population 2015

1.2 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.2 (0.71–1.8)	100 (60–151)
Mortality (HIV+TB only)	<0.01 (0–0.019)	0.32 (0–1.6)
Incidence (includes HIV+TB)	5.9 (3.8–8.4)	498 (322–712)
Incidence (HIV+TB only)	0.087 (0.053–0.13)	7.3 (4.5–11)
Incidence (MDR/RR-TB)**	0.22 (0.15–0.29)	19 (13–24)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.43 (0.17–0.69)	2.2 (1.1–3.4)	2.7 (1.3–4)
Males	0.49 (0.29–0.69)	2.7 (1.8–3.7)	3.2 (2.1–4.3)
Total	0.92 (0.6–1.2)	5 (3.7–6.3)	5.9 (3.8–8.4)

TB case notifications, 2015

Total cases notified	3 532
Total new and relapse	3 337
- % tested with rapid diagnostics at time of diagnosis	25%
- % with known HIV status	83%
- % pulmonary	85%
- % bacteriologically confirmed among pulmonary	58%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	57% (40–87)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.21 (0.11–0.37)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	24	<1%
- on antiretroviral therapy	24	100%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			120 (110–130)
Estimated % of TB cases with MDR/RR-TB	2.6% (2.3–3)	17% (15–19)	
% notified tested for rifampicin resistance	5%	12%	184
MDR/RR-TB cases tested for resistance to second-line drugs			4
Laboratory-confirmed cases		MDR/RR-TB: 4, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 4, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	84%	3 657
Previously treated cases, excluding relapse, registered in 2014	66%	121
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013	50%	2
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	35% (33–39)

TB financing, 2016

National TB budget (US\$ millions)	3.8
Funding source: 41% domestic, 59% international, 0% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence
Notified (new and relapse)
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



New and relapse
Retreatment, excluding relapse
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)



Unfunded
Funded internationally
Funded domestically